Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q96MU7
UPID:
YTDC1_HUMAN
Alternative names:
Splicing factor YT521
Alternative UPACC:
Q96MU7; Q4W5Q3; Q7Z622; Q8TF35
Background:
YTH domain-containing protein 1, also known as Splicing factor YT521, plays a pivotal role in RNA metabolism. It specifically recognizes and binds N6-methyladenosine (m6A)-containing RNAs, influencing mRNA splicing, processing, and stability. This protein is a key regulator of alternative splicing, interacting with mRNA splicing factors SRSF3 and SRSF10 to modulate exon-inclusion or exon-skipping. Additionally, it is involved in the nuclear export of m6A-containing mRNAs and plays a role in S-adenosyl-L-methionine homeostasis and random X inactivation mediated by Xist RNA.
Therapeutic significance:
Understanding the role of YTH domain-containing protein 1 could open doors to potential therapeutic strategies.